Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Nondiabetic Cardiac Surgical Patients Benefit from Strict Glucose Control

By HospiMedica International staff writers
Posted on 29 Dec 2008
Strict perioperative control of blood glucose levels in patients undergoing surgery is linked to a lower risk of postoperative renal impairment and failure, according to a new study.

Researchers from Onze-Lieve-Vrouw Hospital (Aalst, Belgium) retrospectively analyzed two groups of consecutive patients undergoing cardiac surgery with cardiopulmonary bypass between August 2004 and June 2006. More...
In the first group, which contained 305 patients, no tight glycemic control was implemented. Insulin therapy was initiated at blood glucose levels higher than 150 mg/dl. In the group with tight glycemic control (745 patients), intra- and postoperative blood glucose levels were targeted between 80-110 mg/dl, using the Aalst glycemia insulin protocol. Postoperative renal impairment or failure was evaluated based on serum creatinine, glomerular filtration rate (GFR), and urinary output. The researchers used the Cleveland Clinic Severity Score to compare the predicted versus observed incidence of acute postoperative dialysis between groups.

The results showed that mean blood glucose levels in the Insulin group were lower compared to the control group, from re-warming on cardiopulmonary bypass onwards until intensive care unit (ICU) discharge. In nondiabetics, strict perioperative blood-glucose control was associated with a reduced incidence of renal impairment and failure, as well as a reduced incidence of acute postoperative dialysis. Thirty-day mortality was lower in the Insulin than in the control group, representing a 70% decrease in nondiabetics and 56.1% in diabetics. However, in patients that needed hemodialysis, tight glycemic control did not reduce mortality. The observed overall incidence of acute postoperative dialysis was adequately predicted by the Cleveland Clinic Severity Score in the Control group, but was lower than predicted in the Insulin group. The study was published on December 4, 2008, in Critical Care, a publication of BioMedCentral.

"The fact that relatively short-term tight glycemic control during and after cardiac surgery has such an impact on renal function and mortality, is new,” concluded lead author Patrick Lecomte, M.D., and colleagues. "Avoiding the need for renal replacement therapy is probably a key factor in reducing mortality. The observed 60% reduction in postoperative dialysis in our insulin group may have contributed to decreased mortality rates.”

Related Links:
Onze-Lieve-Vrouw Hospital




Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Adjustable Mobile Barrier
M-458
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.